Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo ...

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

With dengue fever spreading to colder climates, Island Pharmaceuticals is working on a preventative and therapeutic solution.

Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical ...

In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with ...

A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | ...

Dr Arshad Khanani shares insights, including data on anti-VEGF treatment and macular atrophy, fibrosis biomarkers, and PCV combination therapies.

Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...